BIIB vs. BMY
Compare and contrast key facts about Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIIB or BMY.
Correlation
The correlation between BIIB and BMY is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BIIB vs. BMY - Performance Comparison
Loading data...
Key characteristics
BIIB:
-1.49
BMY:
0.59
BIIB:
-2.41
BMY:
1.00
BIIB:
0.72
BMY:
1.12
BIIB:
-0.59
BMY:
0.34
BIIB:
-1.42
BMY:
1.82
BIIB:
31.56%
BMY:
8.95%
BIIB:
28.59%
BMY:
31.46%
BIIB:
-90.00%
BMY:
-70.62%
BIIB:
-73.57%
BMY:
-35.79%
Fundamentals
BIIB:
$18.51B
BMY:
$95.34B
BIIB:
$10.12
BMY:
$2.68
BIIB:
12.48
BMY:
17.48
BIIB:
6.24
BMY:
2.26
BIIB:
1.89
BMY:
2.00
BIIB:
1.09
BMY:
5.50
BIIB:
$9.70B
BMY:
$47.64B
BIIB:
$7.15B
BMY:
$31.43B
BIIB:
$2.15B
BMY:
$16.18B
Returns By Period
In the year-to-date period, BIIB achieves a -17.73% return, which is significantly lower than BMY's -15.35% return. Over the past 10 years, BIIB has underperformed BMY with an annualized return of -10.76%, while BMY has yielded a comparatively higher -0.44% annualized return.
BIIB
-17.73%
6.47%
-20.32%
-42.30%
-14.68%
-16.21%
-10.76%
BMY
-15.35%
-3.46%
-18.67%
18.33%
-11.84%
-1.54%
-0.44%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BIIB vs. BMY — Risk-Adjusted Performance Rank
BIIB
BMY
BIIB vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
BIIB vs. BMY - Dividend Comparison
BIIB has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.21%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.21% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
BIIB vs. BMY - Drawdown Comparison
The maximum BIIB drawdown since its inception was -90.00%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for BIIB and BMY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
BIIB vs. BMY - Volatility Comparison
The current volatility for Biogen Inc. (BIIB) is 9.53%, while Bristol-Myers Squibb Company (BMY) has a volatility of 11.41%. This indicates that BIIB experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
BIIB vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Biogen Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BIIB vs. BMY - Profitability Comparison
BIIB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Biogen Inc. reported a gross profit of 1.80B and revenue of 2.43B. Therefore, the gross margin over that period was 74.1%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
BIIB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Biogen Inc. reported an operating income of 625.20M and revenue of 2.43B, resulting in an operating margin of 25.7%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
BIIB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Biogen Inc. reported a net income of 240.50M and revenue of 2.43B, resulting in a net margin of 9.9%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.